Lipoxygenase inhibitors for the treatment of pancreatic cancer.
Pancreatic cancer has a dismal prognosis with no effective medical therapy. Therefore, there is a need to search for novel targets for cancer prevention and treatment. The lipoxygenases oxygenate arachidonic acid and other 20-carbon fatty acids and their downstream metabolites have been found to mediate several aspects of pancreatic cancer development and growth. Therapeutic agents have been developed against various targets in the lipoxygenase pathways. Many of these were first developed for their anti-inflammatory properties and were subsequently found to have anticancer effects. Such agents include lipoxygenase and 5-lipoxygenase-activating protein inhibitors, leukotriene receptor antagonists and natural products with inhibitory effects on these pathways. Dual lipoxygenase and cyclooxygenase inhibition represents an exciting area of research and drug development.
Kennedy
Timothy J
TJ
Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Chan
Chung-Yip
CY
Ding
Xian-Zhong
XZ
Adrian
Thomas E
TE
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D016859:Lipoxygenase Inhibitors